An all-oral regimen of 3 new direct-acting antiviral agents, with or without ribavirin, has been designated by the U.S. Food and Drug Administration as a "breakthrough therapy" for people with genotype 1 chronic hepatitis C, AbbVie announced this week.
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4095-abbvie-interferon-free-hepatitis-c-combo-gets-fda-breakthrough-status
http://www.hivandhepatitis.com/hepatitis-c/hepatitis-c-topics/hcv-treatment/4095-abbvie-interferon-free-hepatitis-c-combo-gets-fda-breakthrough-status
No comments:
Post a Comment